Sort
15,273 grants matching “antimicrobial resistance”
Molecular mechanisms of uropathogenesis
$500,370Harry L. Mobley · University Of Michigan At Ann Arbor · R01 · FY2021 · AI
MYCOBACTERIAL RESISTANCE TO REACTIVE NITROGEN/OXYGEN
$500,362Weill Medical College Of Cornell Univ · R01 · FY2003 · HL
Determining the contribution of zinc deficiency to perinatal Group B Streptococcus infections
$500,207Jennifer A Gaddy · Vanderbilt University Medical Center · R01 · FY2020 · HD
A novel multifunctional role of diverse substrate binding and import by the Haemophilus Sap transporter
$500,137Kevin M Mason · Research Inst Nationwide Children'S Hosp · R01 · FY2021 · AI
Roles of Peptidases in Chronic Airway Inflammation
$500,070George H Caughey · University Of California, San Francisco · P01 · FY2010 · HL
Second Messenger Nucleotides of Enterococcus faecalis
$500,046Jose A Lemos · University Of Florida · R01 · FY2025 · AI
Chemistry and Biology of Bacterial Sulfonucleotide Reductases
$500,021Kate Suzanne Carroll · Scripps Florida · R01 · FY2011 · GM
Novel Polymer Matrix for Dental Applications
$500,001Robert D Bolskar · Tda Research, Inc. · R44 · FY2018 · DE
**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** THE US IS A GLOBAL PLAYER IN PORK PRODUCTION. THE EFFICIENCY OF PRODUCTION IS DAMPENED BY THE BACTERIUMSTREPTOCOCCUS SUIS, WHICH IS CARRIED BY MOST PIGS. THE RATIONALE OF THIS RESEARCH PROGRAM IS TO DEVELOP NOVEL ANTIMICROBIAL STRATEGIES INDEPENDENT OF ANTIBIOTICS. OUR OVERARCHING HYPOTHESIS IS THAT DELIVERY OF ENGINEERED BACTERIAL VIRUSES OR THEIR PRODUCTS, WILL KILLSTREPTOCOCCUS SUIS, AND LAY A FOUNDATION FOR NOVEL TREATMENT STRATEGIES OFS. SUIS. WE AIM TO ACCOMPLISH OUR OBJECTIVES BY IDENTIFYING AND OPTIMIZING GENE PRODUCTS OF BACTERIAL VIRUSES THAT INFECTS. SUIS, WHICH WILL BE USED TO DEVELOP BENEFICIAL BACTERIA THAT DELIVER THESE GENE PRODUCTS. SUCCESSFUL COMPLETION OF THE PROPOSED WORK WILL DELIVER AN INNOVATIVE STRATEGY TO COMBATS. SUISINDEPENDENT OF ANTIBIOTIC AND VACCINATION TREATMENT, WHICH HAS HAD LIMITED SUCCESS. THE PROPOSED WORK IS IMPORTANT BECAUSE IT CAN POTENTIALLY REDUCE THE USE OF ANTIBIOTICS IN AGRICULTURE TO LOWER ANTIBIOTIC-RESISTANT BACTERIA SELECTION ULTIMATELY. THESE APPROACHES ARE EXPECTED TO IMPROVE ANIMAL WELFARE AND FARM SUSTAINABILITY.
$500,000University Of Wisconsin System · · FY2021 · National Institute of Food and Agriculture
RESPIRATORY INFECTIONS REPRESENT A SIGNIFICANT DISEASE BURDEN ON GOAT PRODUCTION IN THE U.S., HOWEVER, THE SINGLE ANTIBIOTIC LABELED FOR TREATMENT OF RESPIRATORY DISEASE IN GOATS IS NOT EFFECTIVEFOR ALL RESPIRATORY PATHOGENS AFFECTING THIS SPECIES. VETERINARIANS AND PRODUCERS ARE THUS FREQUENTLYFACED WITH THE NEED TO TREAT ANIMALS FOR RESPIRATORY DISEASE WITH ANTIBIOTICS LABELED IN OTHER SPECIESTHAT LACK EFFECTIVENESS AND ESTABLISHED MEAT WITHDRAWALDATA IN GOATS.DUE TO THE SMALL SHARE OF THE MARKET THAT MINOR USESPECIES SUCH AS GOATS REPRESENT IN THE U.S., THERE IS UNFORTUNATELY A LACK OF FINANCIAL INCENTIVE FORDRUG MANUFACTURERS TO PURSUE LABEL CLAIMS FOR THESE MINOR SPECIES DESPITE THE URGENT NEED. OUR SHORT TERMGOAL IS TO COMPLETE THE RESEARCH NECESSARY FOR ESTABLISHING THE CLINICAL EFFECTIVENESSOF TULATHROMYCIN FOR TREATMENT OF RESPIRATORY DISEASE IN NON-LACTATING GOATS, WHICH REPRESENTS A NECESSARY COMPONENT FORAPPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRAION (FDA) FOR LABEL APPROVAL OF THIS MEDICATION. OUR LONG-TERM GOAL IS TOIMPROVE ANTIBIOTIC TREATMENT OPTIONS AND ANTIMICROBIAL STEWARDSHIP IN MINOR USE SPECIES SUCH ASGOATS. TO ACHIEVETHESEGOALS, OUR RESEARCH TEAM WILL COMPLETE A RANDOMIZED CONTROLLED TRIAL OF NATURALLY OCCURRINGRESPIRATORY DISEASE IN GOATS TO ASSESS THEEFFECTIVENESS OF TULATHROMYCIN FOR THIS CONDITION, DOCUMENT THEBACTERIAL CAUSES OF PNEUMONIA IN NON-LACTATINGGOATS IN THE UNITED STATES, AND COLLECT ANTIMICROBIAL RESISTANCE DATA NECESSARY FOR ESTABLISHMENT OF APPROPRIATE TREATMENT GUIDLELINESFOR RESPIRATORY INFECTIONS IN GOATS. WHEN COMPLETED, WE EXPECT THAT OUR WORK WILL LEAD TO IMPROVED HEALTH AND WELFARE OF NON-LACTATING GOATS THROUGH GENERATION OFDATA SUPPORTING THE EFFECTIVE USE OFTULATHROMYCIN FORTREATMENT OF CLINICAL RESPIRATORY DISEASE.THIS DATA WILL THEN BE USED AS PART OF THE APPLICATION FOR FDA LABEL APPROVAL FOR TULATHROMYCINUSE IN GOATS, WHICH WHEN GRANTED WILL IMPROVEMEAT QUALITY ASSURANCE THROUGH ESTABLISHMENT OF AN APPROPRIATE MEAT WITHDRAWAL TIMEFOR SAFE HARVEST AND HUMAN MEAT CONSUMPTIONFOLLOWING TREATMENT.DATA GENERATED FROM THIS PROJECT WILL ALSO BE UTILIZED TO IMPROVEANTIMICROBIAL STEWARDSHIP THROUGH THE GENERATION OF SPECIES-SPECIFIC RECOMMENDATIONS FOR ANTICIPATED TREATMENT EFFECTIVENESS IN GOATS. BY IMPROVING ANTIMICROBIAL STEWARDSHIP IN A FOOD PRODUCING ANIMAL SPECIES, THIS WORK WILL ALSO ASSIST IN THE EFFORT TO DECREASE THE OVERALL BURDEN OF ANTIMICROBIAL RESISTANCE ACROSS HUMAN AND ANIMAL HEALTH.
$500,000Iowa State University Of Science And Technology · · FY2021 · National Institute of Food and Agriculture
Reducing Antimicrobial Overuse Through Targeted Therapy for Patients with Community-Acquired Pneumonia
$500,000Michael B Rothberg · Cleveland Clinic Foundation · R01 · FY2023 · HS
Reducing Use of Antibiotics without a Prescription among Outpatients in a Safety Net Healthcare System
$500,000Barbara Wells Trautner · Baylor College Of Medicine · R01 · FY2019 · HS
CAREER: Metabolic Engineering to Potentiate Immunity and Discover Novel Antivirulence Therapies
$500,000Mark P Brynildsen · Princeton University · · FY2015 · ENG
CAREER: Lipo-cyclic antimicrobial peptidomimetics that disrupt bacterial membranes
$500,000Jianfeng Cai · University Of South Florida · · FY2014 · MPS
MTM1: Network properties of fungal-bacterial interactions: Predictive modeling and functional analysis of the Hawaiian Drosophila gut microbiome
$500,000Joanne Yew · University Of Hawaii · · FY2020 · BIO
Task A03: Refinement of the Hamster Model of C. difficile Disease for Testing of Traditional and Non-Traditional Therapeutics
$500,000Saul Tzipori · Tufts University Boston · N01 · FY2018 · AI
Reducing Antimicrobial Overuse Through Targeted Therapy for Patients with Community-Acquired Pneumonia
$500,000Michael B Rothberg · Cleveland Clinic Foundation · R01 · FY2025 · HS
Reducing Antimicrobial Overuse Through Targeted Therapy for Patients with Community-Acquired Pneumonia
$500,000Michael B Rothberg · Cleveland Clinic Foundation · R01 · FY2022 · HS
Global Network for Women's and Children's Health Research Data Coordinating Center
$500,000Elizabeth M McClure · Research Triangle Institute · U24 · FY2021 · HD
Reducing Antimicrobial Overuse Through Targeted Therapy for Patients with Community-Acquired Pneumonia
$500,000Michael B Rothberg · Cleveland Clinic Foundation · R01 · FY2024 · HS
Implementing Global Health Security Agenda in Pakistan with focus on Strengthened Disease Detection, Surveillance, Antimicrobial resistance and Revitalized Public Health Systems
$500,000Sohail Zahoor Zaidi · National Institute Of Health · U2G · FY2015 · GH
Enhancing Patient Safety by Preventing Urinary Tract Infection in Post-Acute Care
$500,000Lona Mody · University Of Michigan At Ann Arbor · R01 · FY2018 · HS
Reducing Overuse of Antibiotics with Decision Support: The ROADS Study
$500,000Derek J. Williams · Vanderbilt University Medical Center · R01 · FY2023 · HS
Implementation and Evaluation of a Video-based Prospective Feedback Intervention to Improve Antimicrobial Stewardship in Neonatal Intensive Care Units
$500,000Peter James Mendel · Rand Corporation · R18 · FY2019 · HS
Understanding and Informing Early Hospital Antibiotic Prescribing for Potential Infection
$500,000Hallie Christine Prescott · University Of Michigan At Ann Arbor · R01 · FY2019 · HS